Prospective, large-scale clinical trials are needed to validate the observed benefits, evaluate long-term safety, and clarify the impact of SGLT2 inhibitors on cardiovascular outcomes in patients undergoing cancer therapy. The gene discussed is SLC5A2; the disease is cancer.